Can effect of finasteride on prostate-specific antigen be used to decrease repeat prostate biopsy?

Urology

Volumn 68, Issue 6, 2006, Pages 1220-1223

  Handel, Liann Nicole ^a   Agarwal, Saurabh ^a   Schiff, Stephen F ^a   Kelty, Patrick J ^a   Cohen, Steven I ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; LIDOCAINE; PROSTATE SPECIFIC ANTIGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; MALE; PATIENT CODING; PATIENT SELECTION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BIOPSY; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33845304307     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1070     Document Type: Article

References (18)

1. Stroumbakis N., Cookson M.S., Reuter V.E., et al. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 49 suppl (1997) 113-118
2. Norberg M., Egevad L., Holmberg L., et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50 (1997) 562-566
3. Soloway M.S., and Obek C. Periprostatic local anesthesia before ultrasound guided prostate biopsy. J Urol 163 (2000) 172-173
4. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327 (1992) 1185-1191
5. Hodge K.K., McNeal J.E., Terris M.K., et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 (1989) 71-74
6. Cookson M.S. Technical refinements of transrectal ultrasound guided needle biopsy of the prostate. AUA Update Series 20 (2001) 82-86
7. Presti J.C., Chang J.J., Bhargava V., et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163 (2000) 163-167
8. Stamey T.A. Making the most out of six systematic sextant biopsies. Urology 45 (1995) 2-12
9. Rodriguez L.V., and Terris M.K. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 160 (1998) 2115-2120
10. Catalona W.J., Partin A.W., Salwin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer form benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
11. Okegawa T., Kinjo M., Watanabe K., et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10 ng/mL. BJU Int 85 (2000) 708-714
12. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52 (1998) 372-378
13. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163 (2000) 1476-1480
14. Stewart C.S., Leibovich B.C., Weaver A.L., et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166 (2001) 86-92
15. McConnell J.D., Bruskewitz R., Walsh P.C., et al., PROSCAR Long-term Efficacy and Safety Study (PLESS) Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
16. Guess H.A., Gormley G.J., Stoner E., et al. The effect of finasteride on prostate specific antigen: review of available data. J Urol 155 (1996) 3-9
17. Andriole G.L., Guess H.A., Epstein J.I., et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 152 (1998) 195-202
18. Kaplan S.A., Ghafar M.A., Volpe M.A., et al. PSA response to finasteride challenge in men with serum PSA greater than 4 ng/mL and previous negative prostate biopsy: preliminary study. Urology 60 (2002) 464-468